Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $166,096.98 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CEO Jon Congleton sold 18,333 shares of the business's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.06, for a total value of $166,096.98. Following the sale, the chief executive officer now owns 877,608 shares of the company's stock, valued at approximately $7,951,128.48. The trade was a 2.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Mineralys Therapeutics Stock Up 7.8 %

MLYS stock traded up $0.71 during midday trading on Wednesday, reaching $9.83. The company's stock had a trading volume of 246,166 shares, compared to its average volume of 300,241. The business's 50-day simple moving average is $12.37 and its 200-day simple moving average is $12.49. Mineralys Therapeutics, Inc. has a 52 week low of $7.95 and a 52 week high of $16.91. The stock has a market cap of $489.23 million, a PE ratio of -3.01 and a beta of 1.49.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings results on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same period last year, the company posted ($0.57) earnings per share. As a group, equities analysts forecast that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors have recently modified their holdings of MLYS. Franklin Resources Inc. raised its position in shares of Mineralys Therapeutics by 17.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,745,513 shares of the company's stock valued at $21,138,000 after acquiring an additional 262,922 shares during the period. Barclays PLC increased its stake in Mineralys Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 38,218 shares of the company's stock valued at $463,000 after purchasing an additional 28,208 shares in the last quarter. Geode Capital Management LLC raised its holdings in Mineralys Therapeutics by 6.6% in the third quarter. Geode Capital Management LLC now owns 620,853 shares of the company's stock worth $7,520,000 after purchasing an additional 38,527 shares during the period. Wellington Management Group LLP bought a new position in shares of Mineralys Therapeutics during the third quarter worth $775,000. Finally, State Street Corp grew its holdings in shares of Mineralys Therapeutics by 4.0% in the 3rd quarter. State Street Corp now owns 483,766 shares of the company's stock valued at $5,858,000 after buying an additional 18,627 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a report on Tuesday, November 12th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.